Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009, 153(4):251-257 | DOI: 10.5507/bp.2009.043

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER

Lucie Kalinova, Jarmila Indrakova, Petr Bachleda
Department of Surgery II, University Hospital, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic

Backround: Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid organ transplantation in both children and adults. Factors associated with increased risk of PTLD include mismatch of recipient and donor EBV serologic status (seronegative recipient with seropositive donor), and intensive drug-induced immunosuppression.

Methods and results: We searched MEDLINE for articles published since 1970 to January 2009. Search terms included posttransplant lymphoproliferative disorder, immunosuppression, posttransplant malignancy, treatment, antiviral agents, rituximab, interferon alpha, chemotherapy, radiation, surgery. Studies in English of adult and pediatric populations after solid organ transplantation were selected and analyzed.

Conclusion: Screening of patients at risk and balancing the intensity of immunosuppression against the risk of allograft rejection could reduce the risk of developing PTLD. In patients who develop PTLD, the severity and extent of disease should be examined and an individualized treatment plan including immunosuppression reduction and other agents should accordingly be chosen.

Keywords: Posttransplant lymphoproliferative disorder, Lymphoproliferation, Immunosuppression

Received: August 17, 2009; Accepted: October 16, 2009; Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Kalinova, L., Indrakova, J., & Bachleda, P. (2009). POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER. Biomedical papers, 153(4), 251-257. doi: 10.5507/bp.2009.043
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Swin nen LJ. Treatment of organ transplantrelated lymphoma. Hematol Oncol Clin North Am 1997;11:963973. Go to original source... Go to PubMed...
    2. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of posttransplant lymphoproliferative disorders. J Nephrol 1997;10:136145.
    3. Nale snik MA. Clinicopathologic characteristics of posttransplant lymphoproliferative disorders - Recent results. Cancer Res 2002;159:918. Go to original source...
    4. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Posttransplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003;31:145155. Go to original source... Go to PubMed...
    5. Herzig KA, Juffs HG, Norris D, Brown AM, Gill D, Hawley CM et al. A single centre experience of postrenal transplant lymphoproliferative disorder. Transpl Int 2003;16:529536. Go to original source... Go to PubMed...
    6. Shroff R, Rees L. The posttransplant lymphoproliferative disorder: a literature review. Pediatr Nephrol 2004;19:365368. Go to original source... Go to PubMed...
    7. Leblond, V, Sutton, L, Dorent, R, Davi F, Bitker MO, Gabarre J et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observe d in a single center. J Clin Oncol 1995;13:961967. Go to original source...
    8. Hanson MN, Morrison VA, Peterson BA, Stieglbauer KT, Kubic VL, McCormick SR et al. Posttransplant T-cell lymphoproliferative disorders - an aggressive, late complication of solid-organ transplantation. Blood 1996;88:362633. Go to original source...
    9. Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 2004;127:42954. Go to original source... Go to PubMed...
    10. Ravat FE, Spittle MF, Russell-Jones R. Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 2006;54:66872. Go to original source... Go to PubMed...
    11. Rajakariar R, Bhattacharyya M, Norton A, Sheaff M, Cavenagh J, Raftery MJ et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 2004;4:153439. Go to original source... Go to PubMed...
    12. Jamali FR, Otrock ZK, Soweid AM, Al-Awar GN, Mahfouz RA, Haidar GR et al. An overview of the pathogenesis and natural history of post-transplant T-cell lymphoma. Leuk Lymphoma 2007;48:178084. Go to original source... Go to PubMed...
    13. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:175863. Go to original source... Go to PubMed...
    14. Petit B, Le Meur Y, Jaccard A. Paraf F, Robert CL, Bordessoule D et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002;73:26570. Go to original source... Go to PubMed...
    15. Dolcetti R. B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007;7:96101. Go to original source... Go to PubMed...
    16. Cockfield SM. Identifying the patients at risk for posttransplant lymphoproliferative disorder. Transplant Infect Dis 2001;3:7080. Go to original source... Go to PubMed...
    17. Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology 2006;11:35566. Go to original source... Go to PubMed...
    18. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:367372. Go to original source... Go to PubMed...
    19. Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006;81:888 93. Go to original source... Go to PubMed...
    20. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen A et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:42534261.
    21. Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK. Polymorphic Diffuse B-Cell Hyperplasias and Lymphomas in Renal Transplant Recipients. Cancer Res 1981;41:426279.
    22. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA. The Pathology of Posttransplant Lymphoproliferative Disorders Occurring in the Setting of Cyclosporine A Prednisone Immunosuppression. Am J Pathol 1988;133:173192.
    23. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989;135: 977987.
    24. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al. Correlative morphologic and molecular analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood 1995;85:552565. Go to original source...
    25. Harris NL, Ferry JA, Swerlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:814.
    26. Harris NL, Swerlow SH, Frizzera G, Knowles DM. Posttransplant lymphoproliferative disoders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue. Lyon: IARC Press; 2001.p.264269.
    27. Cohen JI. Eppstein-Barr virus infection. N Engl J Med 2000;343:48192. Go to original source... Go to PubMed...
    28. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389399. Go to original source... Go to PubMed...
    29. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney MW. Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center. J Clin Oncol 2009;27:335462. Go to original source... Go to PubMed...
    30. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Posttransplant Lymphoproliferative Disorder in Renal Allograft Recipients. Clinical Experience and Risk Factor Analysis in a Single Center. Transplantation.1993;56:8896. Go to original source... Go to PubMed...
    31. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20:134653. Go to original source... Go to PubMed...
    32. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998;16:2052 59. Go to original source... Go to PubMed...
    33. Penn I. Postransplant Malignancy: the Role of Immunosuppression. Drug Saf 2000;23:10113. Go to original source... Go to PubMed...
    34. Green M. Management of Epstein-Barr Virus-induced Posttransplant Lymphoproliferative Disease in Recipient of Solid Organ Transplantation. AM J Transplant 2001;1:1038. Go to original source...
    35. Gärtner BC, Fischinger J, Schäfer H, Einsele H, Roemer K, Müller- Lantzsch N. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Recent Results. Cancer Res 2002;159:4954. Go to original source... Go to PubMed...
    36. American Society of Transplantation. Epstein-Barr Virus and Lymphoproliferative Disorder after Transplantation. Guidelines for the Prevention and Management of Infectious Complications of Solid Organ Transplantation. Am J Transplant 2004;4(suppl 10): 5965.
    37. Andreone P, Gramenz A, Lorenzini S, Biselli M, Cursaro C, Pileri S, Bernardi M. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003;163:19972004. Go to original source... Go to PubMed...
    38. Caillard S, Lelong C, Pessione F, Moulin, B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant 2006;6:273539. Go to original source... Go to PubMed...
    39. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:21421.
    40. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10:87786.
    41. Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996;154:171217. Go to original source... Go to PubMed...
    42. Levine SM, Angel L, Anzueto A, Susanto I, Peters JI, Sako EY, Bryan CL. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999;116:127377. Go to original source... Go to PubMed...
    43. Opelz G, Henderson R Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.Lancet 1993;342:151416. Go to original source...
    44. Swinnen LJ, Costanza-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:172328. Go to original source... Go to PubMed...
    45. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996;2:5257. Go to original source...
    46. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV et al. Immunosuppression and the risk of posttransplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:8793. Go to original source... Go to PubMed...
    47. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222 25. Go to original source... Go to PubMed...
    48. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006;81:122733. Go to original source... Go to PubMed...
    49. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007;41:185058. Go to original source... Go to PubMed...
    50. Shapiro R, Nalesnik MA, McCauley J, Fedorek S, Jordan ML, Scantlebury VP. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients recieving tacrolimus based immunosuppression. Transplantation 1999;68:185154. Go to original source... Go to PubMed...
    51. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, cost analysis of thymoglobulin therapy with inter mittent dosing based on CD3+ lymphocytes counts in kidney and kidney-pancreastransplant recipients. Transplantation 2002;73:15148. Go to original source... Go to PubMed...
    52. Muti G, Klersy C, Baldanti F. Granata S, Oreste P, Pezzetti L et al. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 2003;122:92733. Go to original source... Go to PubMed...
    53. Humar A, Micheals M. American Society of Transplantation recommendation for screening, monitoring and reporting of infections complications in immunosuppression trial in recipients of organ transplantation. Am J Transplant 2006;6:26274. Go to original source... Go to PubMed...
    54. Tsai DE, Nearey M, Hardy CL, Tomaszewski JE, Kotloff RM, Grossman RA et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder on adult solid organ transplant patients. Am J Transplant 2002;2:94654. Go to original source... Go to PubMed...
    55. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:160411. Go to original source... Go to PubMed...
    56. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:28942900. Go to original source... Go to PubMed...
    57. Funch DP, Brady J, Ko HH, Dreyer NA, Walker AM. Methods and objectives of large US multicenter study of posttransplant lymfoproliferative disorder in renal transplant recipients. Recent results. Cancer Res. 2002;159:818. Go to original source...
    58. Starzl TE, Nalesnik ME, Porter KA, Ho M, Iwatsuki S, Griffith BP et al. Revesibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984;1:58387. Go to original source...
    59. Rees L, Thomas A, Amlot PL. Disappearance of an Epstein-Barr virus-positive post-transplant plasmocytoma with reduction of immunosuppression. Lancet 1998;352:789. Go to original source... Go to PubMed...
    60. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998;92:313747. Go to original source...
    61. Cohen JI. Epstein-Barr virus Lymphoproliferative Disorder Associated with Acquired Immunodeficiency. Medicine 1991;70:13760. Go to original source... Go to PubMed...
    62. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and Mayo Clinic Organized International Concensus Development Meeting. Transplantation 1999;68:151725. Go to original source... Go to PubMed...
    63. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow up of 42 adult patients. Transplantation 2001;71:107688. Go to original source... Go to PubMed...
    64. Van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal Rituximab Treatment for Pediatric Posttransplant Lymphoproliferative Disorder of The Central Nervous System. Pediatr Blood Cancer 2008;50:88688. Go to original source... Go to PubMed...
    65. Snanoudj R, Durrbach A, Leblond V, Caillard S, Hurault De Ligny B, Noel C. Primary brain lymphomas after kidney Transplantation: Presentation and outcome. Transplantation 2003;76:93037. Go to original source... Go to PubMed...
    66. Koffman BH, Kennedy AS, Heyman M, Colonna J, Howell C. Use of Radiation Therapy in Posttransplant Lymphoproliferative Disorder (PTLD) after Live Transplantation. Int J Cancer 2000;90:1049. Go to original source... Go to PubMed...
    67. Hanson MN, Morrison VA, Peterson BA, Stieglbauer KT, Kubic VL, McCormick SR et al. Posttransplant T-cell Lymphoproliferative Disorder An Aggressive, Late Complication of Solid-Organ Trans plantation Blood 1996;88:362633. Go to original source...
    68. EBPG Expert Group on Renal Transplantation. European best practice guideline for renal transplantation. Section IV: long term management of the transplant recipient.IV.6.1. Cancer risk after renal transplantation. Posttransplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002;17:313. Go to original source...
    69. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11:1136. Go to original source... Go to PubMed...
    70. Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P. Efficacy and safety of rituximab in B-cell posttransplant lymphoproliferative disorders: result of prospective multicenter phase 2 study. Blood 2006;107:30537. Go to original source... Go to PubMed...
    71. Balfour IC, Wall d, Luisiri A, Sotelo C, Gross TG. Cyclo phosphamide/ prednisone for combination immunosuppression and therapy of lymphoproliferative disease. J Heart Lung Transplant 1999;18:4925.
    72. Orjuela M, Gross TG, Cheung Y, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone and rituximab) in patient with posttransplant lymphoproliferative disorders following solid organ transplantation. Clin Cancer Res 2003;9:3945S-52S.
    73. Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S et al. Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorder (PTLD) After Treatment With Single-Agent Rituximab. Transplantation 2007;83: 91218. Go to original source... Go to PubMed...
    74. Swinnen LJ, Mullen GM, Carr TJ, Constanzo MR, Fischer RI. Aggressive Treatment for Postcardiac Transplant Lympho proliferation. Blood 1995;86:333340. Go to original source...
    75. Elstrom RL, Andreadis C, Aqiu NA, Ahya VN, Bloom RD, Brozena SC et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:59676. Go to original source... Go to PubMed...
    76. Hierro L, Díez-Dorado R, Díaz C, De la Vega A, Frauca E et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus, Liver Transplant 2008;14:1185 93. Go to original source... Go to PubMed...
    77. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC et al. Interferon Alpha Treatment of Posttransplant Lymphoproliferative Disorder in Recipient of Solid Organ Transplants. Transplantation 1998;66:177079. Go to original source... Go to PubMed...
    78. Crossey AR, Dickenson AM, Proctor SJ, Calvert JE. Effects of Interferon Alpha Therapy on Immune Parameters in Immune thrombocytopenic Purpura. Autoimmunity 1996;24:80100. Go to original source...
    79. Cantarovich M, Barkun JS, Forbes RD. Successful Treatment of Posttransplant Lymphoproliferative Disorder with Interferon-Alpha and Intravenous Immunoglobulin. Clin Transplant 1998;12:109 13.
    80. Merlo A, Turrini R, Dolcetti R, Zanovello P, Amadori A. Adoptive Cell Therapy Against EBV-related malignancies: A Survey of Clinical Results. Expert Opin Biol Ther 2008;8:126594. Go to original source... Go to PubMed...
    81. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current Understanding of the Role of EpsteinBarr Virus in Lymphomagenesis and Therapeutic Approaches to EBV-associated Lymphomas. Leuk Lymphoma 2008;49:2734. Go to original source... Go to PubMed...

    Return to the content